Subgroup Insights in Early Relapse Multiple Myeloma

In this segment on early relapse multiple myeloma, Luciano Costa asks Carol Ann Huff to interpret subgroup findings from phase 3 data, with a focus on patients who are anti-CD38–exposed or refractory. Dr. Huff notes that these subgroups represent a clinically challenging population, as prior exposure or resistance to key backbone therapies often limits subsequent treatment options and is associated with less durable responses. She highlights that the observed efficacy in these patients is particularly meaningful, suggesting that BCMA-directed approaches may provide an effective option even in the context of prior anti-CD38 therapy. The discussion also underscores the importance of distinguishing between exposure and true refractoriness when interpreting outcomes. These findings contribute to ongoing considerations around whether such therapies may be positioned earlier in the treatment course, especially for patients with limited alternatives. Overall, the segment emphasizes the relevance of subgroup data in informing treatment strategies in multiple myeloma.